How to Buy Compass Therapeutics Stock
Compass Therapeutics Inc
Compass Therapeutics, Inc. , a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases.
Compass Therapeutics stock last closed at $1.78, up 1.71% from the previous day, and has increased 19.46% in one year. It has overperformed other stocks in the Biotechnology industry by 0.97 percentage points. Compass Therapeutics stock is currently +132.68% from its 52-week low of $0.77, and -56.37% from its 52-week high of $4.08.
There are currently 138.28M CMPX shares outstanding. The market cap of CMPX is $246.14M. In the past 24 hours, 794,611 CMPX shares were traded.
How to Buy Compass Therapeutics Stock
Wondering how to invest in Compass Therapeutics stock? Here's how.
- Decide where to buy Compass Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you determine where to buy Compass Therapeutics stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Fund your investment account: Pick your payment method and add your information.
- Research Compass Therapeutics stock: The Compass Therapeutics ticker symbol is CMPX. Is Compass Therapeutics stock a good investment? Should you buy shares of CMPX? How do CMPX's underlying business fundamentals look? Do top analysts think Compass Therapeutics is a good buy? Why has CMPX's stock price moved recently? (Hint: Our stock analysis website can help you figure out if CMPX is a good stock to buy).
- Place your CMPX purchase: Decide if you will purchase CMPX shares at the current market price or use a limit order to purchase CMPX stock at a specific price.
- Get the latest news on your investment in CMPX: Create a watchlist to keep track of your new investment in Compass Therapeutics stock.
Step 1: Decide where to buy Compass Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy CMPX shares.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global financial markets: From Technology to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen your brokerage, you need to fill out some personal info so you can buy CMPX stock today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to start a new brokerage account.
- Send your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you have finished signing up on app for investing, you need to deposit funds:
Check out the walkthrough below for more details depositing money into your investment account.
Step 4: Research Compass Therapeutics stock
Once you have chosen the best place to buy Compass Therapeutics stock, it's very important to analyze their stock before you buy, so you can comprehend the risk as well as the opportunity.
Compass Therapeutics stock data
CMPX Due Diligence Score
WallStreetZen was built to help everyday investors do more accurate fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on CMPX's stock page.
Is CMPX stock undervalued or overvalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge CMPX's fair value.
Using relative valuations methods:
- CMPX may be undervalued based on its P/B ratio of 1.97x, relative to Biotechnology industry P/B ratio of 4.04x
You can access more valuation research on CMPX's stock here.
A look at CMPX Cashflows and Balance Sheet
Passed Financial Due Diligence Checks:
- CMPX has cash burn of 44899000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the CMPX balance sheet.
- CMPX has $126.72M in cash and short term investments. This is sufficient to cover its annual cash burn of $44.90M.
- Total CMPX debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the CMPX balance sheet.
- CMPX has a low debt to equity ratio of 0.12.
Failed Financial Due Diligence Checks:
- CMPX profit margin has gone down from N/A to -5,808.8% in the past year.
Do Wall Street analysts think it's a good time to buy Compass Therapeutics stock
Out of 6 Equities analysts who track CMPX, the consensus analyst rating on CMPX is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Most Recent CMPX Analyst Ratings
Maury Raycroft, a bottom 8% analyst from Jefferies maintains CMPX with a strong buy rating and raises their CMPX price target from $7.00 to $8.00, on Feb 10, 2025.
You can dive deeper into what analysts are forecasting on the Compass Therapeutics stock forecast page.
Metrics for Advanced CMPX Traders
Who is buying/selling CMPX?
Over the last 12 months, insiders at CMPX have sold more shares than they have bought.
Carl L. Gordon, Director of CMPX, was the latest CMPX insider to sell. They sold $5,678,570.52 worth of CMPX shares on Apr 9, 2025.
Get more info about who owns CMPX stock here.
Does CMPX provide a stable income stream?
No, Compass Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about CMPX?
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Place your CMPX purchase
You have two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly sufficient. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a specific price limit, place a limit order.
Hit the Open button and eToro will execute your order.
If you want additional info about investing in stocks on eToro, click the how to video below:
Step 6: Get the latest news on your investment in CMPX
Now that you own some CMPX stock, you'll want to stay up-to-date on your investment.
Make a watchlist to track the most important metrics related to your CMPX stock.
CMPX Feed
How to Buy Stock in Compass Therapeutics
To reiterate, here are the 6 steps for buying Compass Therapeutics stock:
- Decide where to buy Compass Therapeutics stock
- Sign up for your brokerage account
- Fund your investment account
- Research Compass Therapeutics stock
- Place your CMPX purchase
- Get the latest news on your investment in CMPX
If you require a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep track of your investment in Compass Therapeutics, create a watchlist today.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.